Current reports
Current report No. 47/2021 – Commencement of a phase II clinical trial of a drug based on the innovative JAK/ROCK inhibitor – CPL 409116 – in the treatment of rheumatoid arthritis (RA)
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on 19 November 2021 it submitted an application to the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products for consent to commence a phase II clinical trial of this compound.
Current report No. 46/2021 – Notification about a transaction on subscription warrants of Celon Pharma S.A.
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on November 5, 2021 it received a notification from the person discharging managerial responsibilities in the Company – Mr Jacek Glinka, Vice President of the Company’s Management Board
Current report No. 45/2021 – Allocation of A series subscription warrants to eligible persons under Incentive Programs for Members of the Management Board and other persons of key importance to the Company
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on November 2, 2021 the Supervisory Board and the Management Board of the Company assigned 30,000 A series subscription warrants (“Warrants”) in total to the eligible persons who had made relevant subscriptions; each Warrant entitles them to subscribe for 1 C series share of the Company at the issue price of PLN 0.10 per share.
Current report No. 44/2021 – Adoption of Regulations and implementation of Incentive Programs for Members of the Management Board and other persons of key importance to the Company
The Management Board of Celon Pharma S.A. The “Company” hereby informs that on October 15, 2021 the Supervisory Board and the Management Board of the Company adopted resolutions on the adoption of Regulations of Incentive Programs directed at Members of the Management Board and the Company’s Officers, respectively, and that the implementation of the aforementioned Incentive Programs has already commenced.
Current report No. 43/2021 – Notification about transactions on shares of Celon Pharma S.A.
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on October 8, 2021, Glatton Sp. z o.o. – a person closely related to the person discharging managerial responsibilities, i.e. Mr. Maciej Wieczorek – President of the Management Board of Celon Pharma S.A., sent a notification on transactions conducted on the Company’s shares.
Current report 42/2021 – Registration of D-series shares with the KDPW
The Management Board of Celon Pharma S.A. (the “Company”) hereby announces that it was informed of the publication of an announcement by Krajowy Depozyt Papierów Wartościowych S.A. on the registration in the securities depository of 6,000,000 of the Company’s ordinary D-series bearer shares under ISIN PLCLNPH00015 code on September 22, 2021
Current report 41/2021 – Supplement to Current Report No 35/2021 on the summary of subscription of ordinary D-series bearer shares of Celon Pharma S.A.
The Management Board of Celon Pharma S.A. (the “Company”) hereby publishes a supplement to current report No. 35/2021 dated July 29, 2021 regarding the costs related to the subscription of the Company’s ordinary D-series bearer shares (D-series Shares) referred to in items 12 and 13 of the aforementioned current report:
Current report 40/2021 – Admission and introduction of ordinary D-series bearer shares of the Company to stock exchange trading
The Management Board of Celon Pharma S.A. (the “Company”) hereby announces that on 15 September 2021 the Management Board of the Warsaw Stock Exchange (“GPW”) has adopted a resolution concerning the admission and introduction of the Company’s ordinary D-series bearer shares to stock exchange trading on the GPW Main Market List.
Current report 39/2021 – Conditional registration of the Company’s D-series shares with the KDPW
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs about the statement of the Central Securities Depository of Poland (Krajowy Depozyt Papierów Wartościowych S.A. (“KDPW”), issued on 14 September 2021, on conditional registration in the depository of securities, under ISIN PLCLNPH00015 code; 6,000,000 ordinary D-series bearer shares of the Company with a nominal value of PLN 0.10 each.